GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 139 | +11 | 93.68M | $13.96B | +17 | −5 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | — |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | — | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | — | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | — |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | — | 24.13M | $697.01M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 6.09M | — | $175.97M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 6.09M | — | $175.97M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 6.09M | — | $175.97M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 6.09M | — | $175.97M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.51M | — | $101.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 3.51M | — | $101.33M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 3.51M | — | $101.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 3.51M | — | $101.33M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 3.29M | — | $95.04M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 3.29M | — | $95.04M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 2.79M | — | $80.66M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 2.79M | — | $80.66M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 2.14M | — | $61.67M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 1.82M | — | $52.42M | 0.2% | n/c | 1 | SEC ↗ |
| 15 | Norges Bank ✦ (passive) | 1.38M | — | $39.96M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 1.38M | — | $39.73M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 1.38M | — | $39.73M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 814.52K | — | $23.52M | 0.1% | n/c | 1 | SEC ↗ |
| 19 | ARK Investment Management ✦ | 453.59K | — | $13.10M | 0.1% | n/c | 1 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 299.80K | — | $8.66M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 84.75K | — | $2.45M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | PRIMECAP Management ✦ | 66.18K | — | $1.91M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Bridgewater Associates ✦ | 20.20K | — | $583,405 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 481 holders, 137.05M shares, $11.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 20.89K sh · $3.53M
Officer, Director · 7.59K sh · $1.29M
Officer, Director · 9.02K sh · $1.52M
Director · 116 sh · $18,148
Officer · 13.25K sh · $2.20M
Officer · 3.70K sh · $605,286
Officer · 9.93K sh · $1.63M
Officer · 19.01K sh · $3.14M
Officer · 400 sh · $67,168
Officer · 3.46K sh · $579,639
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology